【摘要】 目的研究埃克替尼联合榄香烯治疗晚期非小细胞肺癌(NSCLC)的效果及安全性。方法将于我院进行治疗的60例晚期NSCLC患者按治疗方法不同分为对照组和榄香烯组,各30例。对照组口服埃克替尼,榄香烯组在对照组的基础上使用榄香烯注射液。比较两组的疾病控制率、客观缓解率、MMP-2和T淋巴细胞亚群中CD4+水平、CD4+/CD8+及不良反应发生情况。结果两组的疾病控制率、客观缓解率、不良反应总发生率无显著差异(P>0.05)。治疗后,榄香烯组的MMP-2、CD4+水平、CD4+/CD8+优于治疗前及对照组(P<0.05)。结论埃克替尼联合榄香烯治疗晚期NSCLC的效果显著,能够明显改善机体的免疫力,降低MMP-2水平,且安全性好,值得在临床中推广。更多还原

【Abstract】 Objective To study the effect and safety of icotinib combined with elemene on advanced non-small cell lung cancer(NSCLC). Methods Sixty advanced NSCLC patients treated in our hospital were divided into control group and elemene group by different treatment methods, with 30 cases in each group. The control group took icotinib orally, and the elemene group used elemene injection on the basis of the control group. The disease control rate, objective remission rate,the levels of MMP-2 and CD4+, CD4+/CD8+in T lymphocyte subsets, occurrence of adverse reactions were compared between the two groups. Results There were no significant differences in the disease control rate, objective remission rate and the total incidence of adverse reactions between the two groups(P>0.05). After treatment, the levels of MMP-2, CD4+and CD4+/CD8+in the elemene group were better than those before treatment and in the control group(P<0.05). Conclusion Icotinib combined with elemene in the treatment of advanced NSCLC has a significant effect, it can significantly improve the body’s immunity, reduce the level of MMP-2, with good safety, which is worthy of clinical promotion.更多还原